Lectins, E.g., Concanavalin, Hemagglutinin, Etc. Patents (Class 530/396)
-
Publication number: 20130315955Abstract: The present invention relates to methods of improving the stability and maintaining the potency of recombinant hemagglutinin formulations, in particular, recombinant influenza hemagglutinin (rHA). In particular, Applicants have shown that the stability of rHA formulations may be significantly improved by mutating cysteine residues or by formulating with a reducing agent and sodium citrate.Type: ApplicationFiled: March 15, 2013Publication date: November 28, 2013Applicant: Protein Sciences CorporationInventors: Kathleen Holtz, Erin Matthews, David Rhodes, Indresh Srivastava
-
Publication number: 20130302360Abstract: Problem to be Solved: The present invention provides a novel mucosal adjuvant. Solution: The present invention provides a mucosal adjuvant composition containing at least a composition comprising molecules having a molecular weight in a range of 100 to 300 kDa obtained from cells or culture fluid of Bordetella bronchiseptica. Administration of the mucosal adjuvant composition to a non-human animal at a surface of the mucous membrane can enhance immunity at the surface of mucous membrane. Therefore preventive effects against trans-mucosal infection can be increased by administering an inactivated vaccine against trans-mucosal infection and the mucosal adjuvant composition to a non-human animal at a surface of mucous membrane. The present invention is effective for preventing trans-mucosal infections, including one or more infections of e.g., canine parainfluenza, canine adenovirus, canine coronavirus, canine parvovirus, canine distemper virus, canine herpesvirus, reovirus and pneumovirus.Type: ApplicationFiled: September 27, 2011Publication date: November 14, 2013Applicant: KYORITSU SEIYAKU CORPORATIONInventors: Ken-ichi Asai, Kazuo Kawakami, Masami Mochizuki
-
Publication number: 20130273150Abstract: The present invention relates to the identification of proteins located on the cell surface of dendritic cells or precursors thereof, particularly antigen presenting dendritic cells. In particular, the present invention relates to compounds such as antibodies that bind these proteins. These compounds can be used to detect and/or enrich a subset of dendritic cells or precursors thereof. These compounds can also be used to target antigens to dendritic cells or precursors thereof to modulate a humoral and/or T cell mediated immune response to an antigen, or used to target cytotoxic agents to dendritic cells or precursors thereof involved in diseased states.Type: ApplicationFiled: March 21, 2013Publication date: October 17, 2013Inventors: Mireille Hanna Lahoud, Anna Irene Proietto, Irina Caminschi, Ken Shortman, Andrew Mark Lew, Li Wu, Mark Dexter Wright
-
Publication number: 20130230897Abstract: The purpose is to produce, with high reproducibility, a complex of labeled probes and a carrier, said complex being to be used for detecting and measuring a target substance to be measured with high sensitivity and high stability. The means for accomplishing the purpose is that a label is bound to a probe-water soluble carrier conjugate using specific binding of an avidin compound such as avidin, streptavidin, etc. to biotin, and the binding of the avidin compound to the probe is performed before the binding to the carrier. Namely, after conjugating the avidin compound to a substance which is capable of binding to the target substance, the conjugate is bound to a high-molecule water-soluble carrier to produce a complex of the avidinized probes and the water-soluble carrier. Then the complex of the avidinized probes and the water-soluble carrier is mixed with a biotinylated label.Type: ApplicationFiled: April 13, 2011Publication date: September 5, 2013Applicants: Advanced Life Science Institute, Inc., Eiken Kagaku Kabushiki KaishaInventors: Yoshiyuki Ohiro, Susumu Takayasu
-
Publication number: 20130230918Abstract: Novel collectin related molecules i.e., a novel collectin gene comprising a nucleotide sequence set out in SEQ ID NO: 1, and a novel collectin comprising an amino acid sequence set out in SEQ ID NO: 2, which are expected to exhibit anti-bacterial, anti-viral activity or the like especially in human body, and methods in which these molecules are used are provided.Type: ApplicationFiled: February 10, 2012Publication date: September 5, 2013Applicant: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventor: Nobutaka Wakamiya
-
Publication number: 20130203092Abstract: The present invention provides methods, compositions, apparatus, and kits for assessing glycoforms of proteins as a biomarker for disease. A purified recombinant form of lectin is used as a detector molecule to specifically label target sugars expressed in disease states. The high affinity of recombinant lectin allows for automation of assays that would be used in the diagnosis of diseases such as, but not limited to, cancer or liver disease.Type: ApplicationFiled: February 3, 2012Publication date: August 8, 2013Applicant: INSTITUTE FOR HEPATITIS AND VIRUS RESEARCHInventors: Patrick Robert ROMANO, Anand MEHTA, Timothy M. Block
-
Publication number: 20130171660Abstract: The present invention provides a blood marker for renal cancer, more specifically, a blood marker that can be practically used for clinical diagnosis of renal cancer. The present invention also provides a blood marker that can be practically used for follow-up after treatment such as surgery and during treatment such as medication for renal cancer. A blood marker for renal cancer selected from the group consisting of Galectin-1, Galectin-3, and ?-enolase. Galectin-1 and/or Galectin-3 as a blood marker for renal cancer for use in an examination performed before diagnostic imaging. ?-Enolase as a blood marker for renal cancer for use in monitoring during and/or after treatment for renal cancer.Type: ApplicationFiled: December 27, 2012Publication date: July 4, 2013Applicants: SHIMADZU CORPORATION, HYOGO COLLEGE OF MEDICINE, EDUCATIONAL CORPORATION MUKOGAWA GAKUINInventors: SHIMADZU CORPORATION, EDUCATIONAL CORPORATION MUKOGAWA GAKUIN, HYOGO COLLEGE OF MEDICINE
-
Publication number: 20130150565Abstract: Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof.Type: ApplicationFiled: June 14, 2011Publication date: June 13, 2013Applicant: Fuso Pharmaceutical Industries, Ltd.Inventors: Nobutaka Wakamiya, Katsuki Ohtani, Takashi Sakamoto, Yuichiro Kishi
-
Publication number: 20130129761Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.Type: ApplicationFiled: March 30, 2011Publication date: May 23, 2013Applicant: Mount Sinai School of MedicineInventors: Adolfo Garcia-Sastre, Peter Palese, John Steel, Anice C. Lowen
-
Publication number: 20130129742Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Applicant: LEUKOLECT ASInventors: Bernt Th. Walther, Mirushe Miftari
-
Publication number: 20130115235Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: October 4, 2012Publication date: May 9, 2013Applicant: MEDIMMUNE, LLCInventor: MEDIMMUNE, LLC
-
Publication number: 20130085267Abstract: The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated C. botulinum carrier complex is provided, where the carrier complex lacks a native neurotoxin subunit.Type: ApplicationFiled: December 15, 2010Publication date: April 4, 2013Applicant: ALLERGAN, INC.Inventors: Jennifer L. Ton, Ronald C. Bates, Ji Zheng, Phillip P. Nguyen, Timothy E. O'Neill
-
Publication number: 20130065258Abstract: The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.Type: ApplicationFiled: January 28, 2011Publication date: March 14, 2013Inventors: Makoto Watanabe, Ei-ichi Matsuo, Naoki Kaneko, Toshiya Matsubara, Osamu Nishimura, Masaki Mori, Ichiro Takemasa
-
Publication number: 20130035283Abstract: The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis.Type: ApplicationFiled: January 19, 2011Publication date: February 7, 2013Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Michael Super, Jeffrey Charles Way, Donald E. Ingber
-
Publication number: 20130028933Abstract: Methods of stabilizing solutions with enveloped vims-based virus-like particles containing an influenza antigen and such stabilized solutions are described.Type: ApplicationFiled: December 28, 2010Publication date: January 31, 2013Applicant: LigoCyte Pharmaceuticals, Inc.Inventors: Joel R. Haynes, Bryan Steadman
-
Patent number: 8357522Abstract: The present invention provides a novel material useful for selectively isolating a cell such as monocyte and the like or a protein from a body fluid and a production method thereof, a physiological material using the material and an isolation material using the physiological material, as well as a method of harvesting a cell such as monocyte and the like using the isolation material, a method of harvesting a protein and a method of preparing a dendritic cell.Type: GrantFiled: May 25, 2007Date of Patent: January 22, 2013Assignee: Kaneka CorporationInventors: Hiroshi Awaji, Ashutosh Kumar, Akira Kobayashi, Naohiro Imai
-
Publication number: 20130018178Abstract: The present invention concerns a new method for the purification of Heparin Binding Hemagglutinin (HBHA) robust and reproducible at an industrial scale. The purification is made from HBHA-producing microorganisms extracted in presence of a detergent, a solvent or a chaotropic agent, followed by a first elution on ion exchange resins. In a preferred embodiment, the elution on ion exchange resins is followed by a second chromatography on mixed mode sorbents.Type: ApplicationFiled: June 22, 2010Publication date: January 17, 2013Applicant: PX THERAPEUTICSInventors: Aurelie Laronze, Nicolas Mouz, Joana Pech
-
Publication number: 20130004529Abstract: Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed.Type: ApplicationFiled: April 27, 2012Publication date: January 3, 2013Inventors: David B. Weiner, Jian Yan, Dominick Laddy
-
Publication number: 20120328568Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.Type: ApplicationFiled: February 11, 2011Publication date: December 27, 2012Applicant: EMORY UNIVERSITYInventors: Richard D Cummings, Sean R. Stowell, Connie Arthur
-
Patent number: 8323665Abstract: The present invention provides methods to produce toxoid vaccines, such as ricin A chain vaccines, with reduced ability to promote vascular leak syndrome (VLS) and catalytic toxicity associated with various proteinaceous toxins, such as ribosome inactivating proteins. The invention also provides toxoids which have been mutated to lack amino acid sequences which induce VLS and toxic catalytic activity.Type: GrantFiled: February 12, 2007Date of Patent: December 4, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Ellen S. Vitetta, Victor F. Ghetie, Joan E. Smallshaw, Roxana G. Baluna
-
Publication number: 20120301504Abstract: The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria.Type: ApplicationFiled: November 2, 2010Publication date: November 29, 2012Applicant: The Gov't of the USA As Represented by the Secreta ry of the Dept. of Health and Human Services, NatInventors: Surender Khurana, Hana Golding
-
Publication number: 20120288871Abstract: Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.Type: ApplicationFiled: July 24, 2012Publication date: November 15, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Wai-Yee Leung, Ching-Ying Cheung, Stephen Yue
-
Publication number: 20120277413Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.Type: ApplicationFiled: April 23, 2012Publication date: November 1, 2012Applicant: Miltenyi Biotech GmbHInventors: Juergen Schmitz, Andrzej Dzionek, David William Buck
-
Publication number: 20120270255Abstract: The disclosure relates to the development of improved methods for quantifying antigen in a vaccine composition in the absence of available antigen standards. More specifically, the disclosure provides fast and robust methods of separating antigens from vaccine compositions, comprising the steps of solubilizing antigen without detergent and without alkylation, using acidification to prevent antigen subtypes from binding again, isolating antigen subtypes with chromatography, and quantifying the eluted antigen with amino acid analysis. The methods of the disclosure are applicable for use with a variety of antigens, thereby providing an improved method in the art of vaccine manufacturing to date.Type: ApplicationFiled: April 18, 2012Publication date: October 25, 2012Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Michael Graninger, Martin Kaliwoda
-
Publication number: 20120258077Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: ApplicationFiled: June 14, 2012Publication date: October 11, 2012Applicant: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Patent number: 8283452Abstract: Described are methods for separating hemagglutinin (HA) antigens, comprising the steps of applying a reduced and derivatized antigen preparation comprising solubilized HA antigens and a detergent in a pH controlled solution, on a Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) column; and eluting the HA antigens from the column with an ion pairing agent in an organic mobile phase. The invention further relates to quantifying methods using the methods for separating the antigens with the further step of measuring the peak area of the eluted antigen in a chromatogram resulting from the elution step.Type: GrantFiled: October 2, 2009Date of Patent: October 9, 2012Assignee: Crucell Holland B.V.Inventors: Johan C. Kapteyn, Fija M. Lagerwerf
-
Publication number: 20120244600Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: December 1, 2011Publication date: September 27, 2012Applicant: MedImmune, LLCInventor: Hong JIN
-
Publication number: 20120231459Abstract: A novel method is disclosed for simultaneous detection and quantification of two or more nucleic acid targets, without need for amplification. The method depends on spectral-temporal resolution of chemiluminescence emitted from independent hybridization-induced chemiluminescent signal (HICS) probes. The utility of this method has been demonstrated by use of resolvable N-linked acridinium and 2,7-dimethoxyacridinium ester labeled probes in a homogeneous assay for sensitive and simultaneous independent quantification of several bacterial and fungal target sequences. Compositions and kits for practicing the method of the present invention are also disclosed.Type: ApplicationFiled: April 12, 2012Publication date: September 13, 2012Applicant: GEN-PROBE INCORPORATEDInventors: Kenneth A. BROWNE, Ian WEEKS
-
Publication number: 20120219587Abstract: A process for producing a split influenza virus preparation or subunit influenza preparation comprising the steps of: (i) providing a whole virus preparation; (ii) splitting the whole virus preparation in the presence of a first detergent; (iii) adding t-octylphenoxypolyethoxyethanol (TRITON X-100â„¢) to the resulting split virus preparation; and (iv) filtering the split virus preparation.Type: ApplicationFiled: October 25, 2010Publication date: August 30, 2012Inventors: Erik Jozef D' Hondt, Hans Bernd Engelmann
-
Publication number: 20120219580Abstract: The present invention relates to a method for producing transgenic plants, which involves producing hemagglutinin proteins of the H5N1 virus using a plant transformation recombinant vector, wherein said vector can express hemagglutinin proteins of the H5N1 virus, the highly pathogenic avian influenza virus, and transport proteins expressed in plants to the endoplasmic reticulum and enable the retention of the proteins in the endoplasmic reticulum to enable glycosylation required for antigen activity. The present invention also relates to a method for the mass production of hemagglutinin proteins of the antigenic H5N1 virus from transgenic plants or a vaccine composition for the avian influenza virus comprising the transgenic plants or the hemagglutinin proteins produced from the plants. The transgenic plants can be used as edible vaccines, antigenic hemagglutinin proteins produced can be used as protein vaccines for the H5N1 avian influenza virus, or as diagnostic reagents for avian influenza virus infection.Type: ApplicationFiled: October 6, 2010Publication date: August 30, 2012Applicant: Helix, Co., LimitedInventors: In Hwan Hwang, Eun Ju Sohn, Eun Hye Kwon, Yun Jeong Na, Eun Hyun Jeon, Se Jin Im, Ki Seok Park, Young Chul Sung
-
Publication number: 20120219585Abstract: The present invention provides, among other things, methods, reagents, and systems for the treatment, detection, analysis, and/or characterization of influenza infections.Type: ApplicationFiled: September 21, 2011Publication date: August 30, 2012Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Rahul Raman, Xiaoying Koh, Karthik Viswanathan, Ram Sasisekharan, Aarthi Chandrasekaran
-
Publication number: 20120219584Abstract: Immunogens and compositions are provided that encode a protein comprising an influenza A subtype H1 hemagglutinin glycan-shielded receptor binding domain A (RBD A) region and at least one influenza A subtype H1 hemagglutinin antigenic site wherein the antigenic site is not within the RBD-A region. Also provided are immunogens and compositions that encode an immunogenic protein comprising at least one epitope of the RBD-A region of a pandemic influenza A subtype H1 hemagglutinin antigen. Also provided are such proteins, nucleic acids that encode such proteins, and antibodies against such proteins. Also provided are methods to use such immunogens and compositions to elicit a neutralizing antibody immune response against influenza A subtype H1 virus.Type: ApplicationFiled: October 5, 2010Publication date: August 30, 2012Applicant: THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTHInventors: Gary J. Nabel, Chih-Jen Wei, Zhi-Yong Yang, Jeffrey Boyington
-
Publication number: 20120213819Abstract: The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.Type: ApplicationFiled: October 4, 2011Publication date: August 23, 2012Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Kannan Tharakaraman, Karthik Viswanathan, Rahul Raman, Ram Sasisekharan
-
Publication number: 20120174264Abstract: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.Type: ApplicationFiled: March 8, 2012Publication date: July 5, 2012Inventors: Hilary Koprowski, Natalia Pogrebnyak, Maxim Golovkin
-
Publication number: 20120124683Abstract: The present invention relates, in general, to siRNA and, in particular, to a method of effecting targeted delivery of siRNAs and to compounds suitable for use in such a method.Type: ApplicationFiled: June 29, 2011Publication date: May 17, 2012Applicant: DUKE UNIVERSITYInventors: Bruce A. Sullenger, Paloma H. Giangrande, James McNamara
-
Publication number: 20120088262Abstract: Cyanine compounds having the general formula I, conjugates, complexes, and compositions comprising the cyanine compounds are provided. Fluorescence resonance energy transfer (FRET) dye pairs and viability dyes are also provided.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Applicant: Millipore CorporationInventors: Ali Dehghani, Kamala Tyagarajan, Kimvan Tran
-
Publication number: 20120058145Abstract: A method of purifying a virus, or a viral antigen thereof, from a culture of infected cells comprising at least the steps of: (a) collecting the virus-containing cell culture medium, and (b) purifying the virus, wherein at least one homogenization step is implemented during the purification to obtain a virus homogenate.Type: ApplicationFiled: May 6, 2010Publication date: March 8, 2012Inventors: Bruno Rene Andre, Benoit Paul Suzanne Champluvier
-
Publication number: 20120052071Abstract: The invention provides newly identified proteins as markers for the detection of tumors, or as targets for their treatment, particularly of tumors affecting lung, colon, breast, ovary; affinity ligands capable of selectively interacting with the newly identified markers; methods of screening a tissue sample for malignancy, for determining the presence of a tumor in a subject and for screening a test compound as an antitumor candidate; a diagnostic kit.Type: ApplicationFiled: January 27, 2010Publication date: March 1, 2012Applicant: Externautics S.p.A.,Inventors: Renata Grifantini, Piero Pileri, Susanna Campagnoli, Andrea Pierleoni, Renzo Nogarotto
-
Publication number: 20120041181Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.Type: ApplicationFiled: January 9, 2009Publication date: February 16, 2012Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
-
Patent number: 8114633Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.Type: GrantFiled: December 22, 2008Date of Patent: February 14, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
-
Publication number: 20120009624Abstract: The invention relates to a protein particle comprising chimeric protein having an aggregating part capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; and a functional part capable of binding to, or being bound by, a target compound. Affinity matrixes comprising the protein particle are also provided.Type: ApplicationFiled: December 3, 2007Publication date: January 12, 2012Inventors: Jens Sommer-Knudsen, Moreland D. Gibbs
-
Publication number: 20110319338Abstract: Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell.Type: ApplicationFiled: December 2, 2009Publication date: December 29, 2011Applicant: The Board of Regents of the University of Texas SystemInventor: Honami Naora
-
Publication number: 20110301057Abstract: The present invention relates to a method of directing in situ oriented immobilization of a protein on a support. This method involves providing a support and contacting the support with a solution. The solution comprises (a) a protein comprising a coupling moiety and (b) a molecule comprising a first group reactive with the support and a second group reactive with the coupling moiety. The molecule binds (i) the support at the first group and (ii) the coupling moiety at the second group, thereby immobilizing and orienting, in situ, the protein on the support. Also described are a protein array and a method of screening compounds for protein interaction.Type: ApplicationFiled: June 3, 2011Publication date: December 8, 2011Applicant: NEW YORK UNIVERSITYInventors: Daniel C. PROPHETER, Lara K. MAHAL
-
Publication number: 20110286958Abstract: Polymeric platinum amidomalonate complexes, where the platinum is in +2 or +4 oxidation state, and where the complexes optionally contain tumor seeking groups, are useful in the treatment of cancer.Type: ApplicationFiled: May 16, 2011Publication date: November 24, 2011Inventors: Paul Sood, N. Rao Ummaneni, Bruce Thurmond, Ryszard Zarzycki
-
Publication number: 20110281792Abstract: In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with glucose for binding with the lectins at said binding sites and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between lectins and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of glucose. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label.Type: ApplicationFiled: January 27, 2010Publication date: November 17, 2011Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20110275560Abstract: The present disclosure provides a cross-linked material comprising conjugates which include two or more separate affinity ligands bound to a non-polymeric framework, wherein the molecular weight of the non-polymeric framework is less than 10,000 Da; and multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby cross-link the conjugates to form a cross-linked material, wherein the non-covalent bonds between the multivalent cross-linking agents and the affinity ligands are competitively dissociated in the presence of excess amounts of a target molecule. The present disclosure also provides methods of making and methods of using these materials. In other aspects, the present disclosure provides exemplary conjugates including conjugates for use in glucose responsive cross-linked materials.Type: ApplicationFiled: January 27, 2010Publication date: November 10, 2011Inventors: Todd C. Zion, Thomas M. Lancaster
-
Publication number: 20110206618Abstract: Provided is a fluorescent labeling material, including zinc oxide nanoparticles each surface-modified with an organic compound having an amino group placed at an outer end thereof. Also provided is a fluorescent labeling agent to be used in vivo or in vitro, including the fluorescent labeling material, in which: EDC or the like is bound thereto through the amino group; and a substance capable of selectively binding to a target to be fluorescently labeled, such as an antibody, is linked thereto.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Applicant: NATIONAL UNIVERSITY CORPORATION SHIMANE UNIVERSITYInventors: Moriyuki Sato, Morihiko Nakamura
-
Publication number: 20110178020Abstract: Isolated fusion polypeptides are provided that are comprised of a cell-penetrating polypeptide and a SNARE polypeptide aptamer. Further provided are methods for inhibiting neutrophil granule exocytosis that comprise contacting a neutrophil with a fusion polypeptide including a cell-penetrating polypeptide and a SNARE polypeptide aptamer such that the fusion polypeptide enters the neutrophil and inhibits neutrophil granule exocytosis. Also provided are methods for treating a neutrophil-mediated inflammatory disorder by inhibiting SNARE-associated exocytosis in neutrophils.Type: ApplicationFiled: July 28, 2009Publication date: July 21, 2011Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.Inventors: Kenneth R. McLeish, Silvia M. Uriarte, Madhavi J. Rane
-
Patent number: 7959929Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 19, 2006Date of Patent: June 14, 2011Assignees: University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Intervet International B.V.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Publication number: 20110136137Abstract: The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. The biomarkers are selected from a first group consisting of Amy 1, Apo Al, Carbx, Casp, AFP, ApoM, SAP, Fib-a, Fib-b, Fib-g, ApoE, A2MG, A2MG isoform, Serpin, Clusterin, MHC-fB, SAP isoform, or from a second group consisting of Gpx3, properidin, MUP1, HMW-K, Lifr-p, Orm 1, MBL-A, MBP-C, wherein the biomarkers are regulated by EGF overexpression in a subject.Type: ApplicationFiled: December 11, 2008Publication date: June 9, 2011Inventors: Jurgen Borlak, Guiseppe Gazzana